UPDATE: Morgan Keegan Lowers PT on Haemonetics to $63

Morgan Keegan is out with its report today on Haemonetics

, lowering its PT from $65 to $63. In its report, Morgan Keegan writes, "In our opinion, the significant positive highlight in the quarter was accelerating top-line growth, which was primarily driven by a 14% increase in plasma sales. Conversely, EPS guidance was lowered by 10% mostly due to items related to quality improvement and delay in operational cost savings, and hospital product sales. Consequently, we are reducing our estimate for fiscal 2013 to $3.65 from $3.93 and are maintaining our Market Perform rating. We have adjusted our price target to $63 from $65 to account for our lower EPS expectations in fiscal 2013. Should Haemonetics shares dislocate to the mid-$50's, we would look to get more aggressive on the stock." Morgan Keegan maintains Market Perform on HAE. Shares of HAE closed Monday at $60.95, down 4.54% from Friday's close.